296 related articles for article (PubMed ID: 33468556)
1. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
[TBL] [Abstract][Full Text] [Related]
3. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
5. Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.
Lazarus G; Budiman RA; Rinaldi I
Cancer Immunol Immunother; 2022 Feb; 71(2):373-386. PubMed ID: 34173850
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibition in COVID-19: risks and benefits.
Pezeshki PS; Rezaei N
Expert Opin Biol Ther; 2021 Sep; 21(9):1173-1179. PubMed ID: 33543652
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
8. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
[TBL] [Abstract][Full Text] [Related]
9. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
10. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A; Dettorre GM; Dafni U; Aguilar-Company J; Castelo-Branco L; Lambertini M; Gennatas S; Angelis V; Sita-Lumsden A; Rogado J; Pedrazzoli P; Viñal D; Prat A; Rossi M; Berardi R; Alonso-Gordoa T; Grisanti S; Dimopoulou G; Queirolo P; Pradervand S; Bertuzzi A; Bower M; Arnold D; Salazar R; Tucci M; Harrington KJ; Mazzoni F; Mukherjee U; Tsourti Z; Michielin O; Pommeret F; Brunet J; Vincenzi B; Tonini G; Patriarca A; Biello F; Krengli M; Tabernero J; Pentheroudakis G; Gennari A; Peters S; Romano E; Pinato DJ
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450384
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
[TBL] [Abstract][Full Text] [Related]
13. Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.
Shen C; Li Q; Wei Y; Li Y; Li J; Tao J
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303577
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study.
Murthy S; Archambault PM; Atique A; Carrier FM; Cheng MP; Codan C; Daneman N; Dechert W; Douglas S; Fiest KM; Fowler R; Goco G; Gu Y; Guerguerian AM; Hall R; Hsu JM; Joffe A; Jouvet P; Kelly L; Kho ME; Kruisselbrink RJ; Kumar D; Kutsogiannis DJ; Lamontagne F; Lee TC; Menon K; O'Grady H; O'Hearn K; Ovakim DH; Pharand SG; Pitre T; Reel R; Reeve B; Rewa O; Richardson D; Rishu A; Sandhu G; Sarfo-Mensah S; Shadowitz E; Sligl W; Solomon J; Stelfox HT; Swanson A; Tessier-Grenier H; Tsang JLY; Wood G;
CMAJ Open; 2021; 9(1):E181-E188. PubMed ID: 33688026
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Lièvre A; Turpin A; Ray-Coquard I; Le Malicot K; Thariat J; Ahle G; Neuzillet C; Paoletti X; Bouché O; Aldabbagh K; Michel P; Debieuvre D; Canellas A; Wislez M; Laurent L; Mabro M; Colle R; Hardy-Bessard AC; Mansi L; Colomba E; Bourhis J; Gorphe P; Pointreau Y; Idbaih A; Ursu R; Di Stefano AL; Zalcman G; Aparicio T;
Eur J Cancer; 2020 Dec; 141():62-81. PubMed ID: 33129039
[TBL] [Abstract][Full Text] [Related]
16. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N; Boussier J; Tetu P; Smith N; Bruel T; Charbit B; Barnabei L; Corneau A; Da Meda L; Allayous C; Baroudjian B; Jebali M; Herms F; Grzelak L; Staropoli I; Calmettes V; Hadjadj J; Peyrony O; Cassius C; LeGoff J; Kramkimel N; Aractingi S; Fontes M; Blanc C; Rieux-Laucat F; Schwartz O; Terrier B; Duffy D; Lebbé C
Sci Adv; 2021 Aug; 7(34):. PubMed ID: 34407944
[TBL] [Abstract][Full Text] [Related]
18. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study.
Patone M; Thomas K; Hatch R; Tan PS; Coupland C; Liao W; Mouncey P; Harrison D; Rowan K; Horby P; Watkinson P; Hippisley-Cox J
Lancet Infect Dis; 2021 Nov; 21(11):1518-1528. PubMed ID: 34171232
[TBL] [Abstract][Full Text] [Related]
19. Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Mostaghim A; Minkove S; Aguilar-Company J; Ruiz-Camps I; Eremiev-Eremiev S; Dettorre GM; Fox L; Tondini C; Brunet J; Carmona-García M; Lambertini M; Bower M; Newsom-Davis T; Sharkey R; Pria AD; Rossi M; Plaja A; Salazar R; Sureda A; Prat A; Michalarea V; Van Hemelrijck M; Sita-Lumsden A; Bertuzzi A; Rimassa L; Rossi S; Rizzo G; Pedrazzoli P; Lee AJ; Murphy C; Belessiotis K; Diamantis N; Mukherjee U; Pommeret F; Stoclin A; Martinez-Vila C; Bruna R; Gaidano G; D'Avanzo F; Gennari A; Athale J; Eichacker P; Pinato DJ; Torabi-Parizi P; Cortellini A;
Int J Infect Dis; 2024 Feb; 139():13-20. PubMed ID: 38029831
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.
Rüthrich MM; Giessen-Jung C; Borgmann S; Classen AY; Dolff S; Grüner B; Hanses F; Isberner N; Köhler P; Lanznaster J; Merle U; Nadalin S; Piepel C; Schneider J; Schons M; Strauss R; Tometten L; Vehreschild JJ; von Lilienfeld-Toal M; Beutel G; Wille K;
Ann Hematol; 2021 Feb; 100(2):383-393. PubMed ID: 33159569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
